CIK 0001582313 · Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980661854
- Phone
- (604) 484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-11 | Von Seggern Christopher Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-03-11 | AULIN SHERRY Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-03-11 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-03-11 | EMPFIELD JAMES R. EVP, Drug Discovery | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2024-03-11 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2024-03-11 | DiFabio Andrea Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-03-11 | MORTIMER IAN PRESIDENT & CEO | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2024-03-08 | GAROFALO ELIZABETH A. Director | Option exercise | +3,500 | $18.56 | $65K | 3,500 |
| 2024-03-08 | GAROFALO ELIZABETH A. Director | Shares withheld for taxes | −1,408 | $46.16 | $65K | 2,092 |
| 2024-03-08 | GAROFALO ELIZABETH A. Director | Sale | −2,092 | $45.69 | $96K | 0 |
| 2024-03-08 | GAROFALO ELIZABETH A. Director | Option exercise · Stock Option (Right to Buy) | −3,500 | 16,500 | ||
| 2024-03-07 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise | +1,234 | $9.85 | $12K | 9,632 |
| 2024-03-07 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Shares withheld for taxes | −215 | $45.96 | $10K | 9,417 |
| 2024-03-07 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise | +7,407 | $9.85 | $73K | 16,824 |
| 2024-03-07 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Shares withheld for taxes | −1,289 | $45.96 | $59K | 15,535 |
| 2024-03-07 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −1,019 | $46.15 | $47K | 14,516 |
| 2024-03-07 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −6,118 | $46.30 | $283K | 8,398 |
| 2024-03-07 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise · Stock Option (Right to Buy) | −1,234 | 0 | ||
| 2024-03-07 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Option exercise · Stock Option (Right to Buy) | −7,407 | 0 | ||
| 2024-03-07 | GANNON STEVEN Director | Sale | −1,000 | $46.45 | $46K | 14,000 |
Page 9 of 16 · 308 trades